Adaptive Biotechnologies (NASDAQ:ADPT) Insider Susan Bobulsky Sells 11,000 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Susan Bobulsky sold 11,000 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $18.00, for a total transaction of $198,000.00. Following the completion of the transaction, the insider directly owned 416,775 shares in the company, valued at approximately $7,501,950. The trade was a 2.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Susan Bobulsky also recently made the following trade(s):

• On Wednesday, March 11th, Susan Bobulsky sold 41,338 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.17, for a total transaction of $544,421.46.

Adaptive Biotechnologies Trading Down 1.2%

Shares of Adaptive Biotechnologies stock traded down $0.20 during trading on Monday, hitting $16.70. The stock had a trading volume of 1,749,340 shares, compared to its average volume of 1,691,541. The firm has a market cap of $2.67 billion, a price-to-earnings ratio of -50.61 and a beta of 2.16. Adaptive Biotechnologies Corporation has a 12 month low of $9.90 and a 12 month high of $20.76. The business’s 50-day moving average is $14.22 and its 200 day moving average is $15.65.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.03. The firm had revenue of $70.87 million for the quarter, compared to analysts’ expectations of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The business’s quarterly revenue was up 35.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.20) earnings per share. As a group, equities analysts expect that Adaptive Biotechnologies Corporation will post -0.48 EPS for the current year.

Institutional Trading of Adaptive Biotechnologies

Several institutional investors have recently added to or reduced their stakes in ADPT. AQR Capital Management LLC boosted its position in Adaptive Biotechnologies by 45.8% during the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock valued at $2,265,000 after buying an additional 97,444 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Adaptive Biotechnologies by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock valued at $511,000 after buying an additional 2,914 shares during the period. Caxton Associates LLP purchased a new stake in Adaptive Biotechnologies during the first quarter valued at about $93,000. New York State Common Retirement Fund boosted its position in Adaptive Biotechnologies by 39.2% during the second quarter. New York State Common Retirement Fund now owns 47,258 shares of the company’s stock valued at $551,000 after buying an additional 13,300 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its position in Adaptive Biotechnologies by 728.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company’s stock valued at $4,417,000 after buying an additional 333,379 shares during the period. 99.17% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ADPT. JPMorgan Chase & Co. cut their target price on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. TD Cowen upped their target price on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. BTIG Research reiterated a “buy” rating and issued a $22.00 target price on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. Finally, Guggenheim reiterated a “buy” rating and issued a $21.00 target price on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $19.57.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.